CA3015519A1 - Method and composition for treating cancer or skin lesion using a vaccine - Google Patents

Method and composition for treating cancer or skin lesion using a vaccine Download PDF

Info

Publication number
CA3015519A1
CA3015519A1 CA3015519A CA3015519A CA3015519A1 CA 3015519 A1 CA3015519 A1 CA 3015519A1 CA 3015519 A CA3015519 A CA 3015519A CA 3015519 A CA3015519 A CA 3015519A CA 3015519 A1 CA3015519 A1 CA 3015519A1
Authority
CA
Canada
Prior art keywords
hpv
vaccine
dose
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015519A
Other languages
English (en)
French (fr)
Inventor
Tim Ioannides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of CA3015519A1 publication Critical patent/CA3015519A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3015519A 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine Pending CA3015519A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US62/300,785 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US62/328,487 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US62/338,183 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US62/444,576 2017-01-10
US201762455434P 2017-02-06 2017-02-06
US62/455,434 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
CA3015519A1 true CA3015519A1 (en) 2017-08-31

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015519A Pending CA3015519A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Country Status (16)

Country Link
EP (1) EP3419661A4 (https=)
JP (3) JP2019506435A (https=)
KR (1) KR102873848B1 (https=)
CN (1) CN108883168A (https=)
AU (1) AU2017223970B2 (https=)
BR (1) BR112018067550A2 (https=)
CA (1) CA3015519A1 (https=)
CL (1) CL2018002438A1 (https=)
CO (1) CO2018009205A2 (https=)
HK (1) HK1256935A1 (https=)
IL (1) IL261340B2 (https=)
MX (1) MX2018010338A (https=)
MY (1) MY194694A (https=)
SG (1) SG11201807080UA (https=)
WO (1) WO2017147475A1 (https=)
ZA (1) ZA201805679B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
PL4225351T1 (pl) * 2020-10-12 2023-12-11 Hpvvax, Llc Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym
WO2024097051A1 (en) * 2022-10-31 2024-05-10 Pyrojas Inc. Immunotherapy compositions and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP3427755B1 (en) * 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
SG177269A1 (en) * 2009-06-25 2012-02-28 Glaxosmithkline Biolog Sa Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) * 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine
JP7037884B2 (ja) * 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
EP3419661A4 (en) 2019-10-23
KR102873848B1 (ko) 2025-10-17
JP2023110038A (ja) 2023-08-08
BR112018067550A2 (pt) 2019-10-01
AU2017223970B2 (en) 2022-01-27
EP3419661A1 (en) 2019-01-02
JP2019506435A (ja) 2019-03-07
CO2018009205A2 (es) 2018-09-20
MY194694A (en) 2022-12-15
JP2021155448A (ja) 2021-10-07
MX2018010338A (es) 2018-11-09
HK1256935A1 (zh) 2019-10-04
ZA201805679B (en) 2019-11-27
AU2017223970A1 (en) 2018-09-13
WO2017147475A1 (en) 2017-08-31
CL2018002438A1 (es) 2019-01-04
JP7732784B2 (ja) 2025-09-02
KR20180112043A (ko) 2018-10-11
CN108883168A (zh) 2018-11-23
IL261340A (en) 2018-11-29
IL261340B2 (en) 2023-07-01
SG11201807080UA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
US20240245690A1 (en) Treatment of Respiratory Diseases
JP7732784B2 (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
US20240226213A1 (en) Treatment of Warts
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
CA3219273A1 (en) Use of 5-nitro-8-hydroxyquinoline
WO2022206086A1 (zh) 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
CN118948873B (zh) 金线莲苷在防治脑胶质瘤中的应用
RU2147841C1 (ru) Способ лечения папилломатоза гортани
JP6663438B2 (ja) 癌および皮膚病変の治療
CN109939223B (zh) 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
WO2022264097A1 (en) Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
TWI418347B (zh) 治療疱疹病毒感染的方法
TW202511290A (zh) 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法
CN107308145A (zh) 苯乙双胍作为皮肤抗炎制剂的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240729

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241212

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250214

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250214

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250506

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250815

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250820

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250929

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251203